1. Introduction {#sec1}
===============

The microenvironment is a dynamic system that is largely composed of inflammatory cells and cytokines, including tumor cells and stroma (the latter of which consists of immune cells and the surrounding extracellular matrix) \[[@B1], [@B2]\]. Under specific stimulation conditions, inflammation can result in the production of antiangiogenic cytokines, which suppress tumor growth. Despite being antagonistic to the action of tumor suppression, in most tumors, inflammatory cells can promote angiogenesis, growth, tumor cell migration, tissue degradation, and remodeling steps that are characteristic of the chronic inflammation associated with intense tissue disorders typical of acute inflammation \[[@B1], [@B3]--[@B7]\].

The transcription factor nuclear kappa B (NF-*κ*B) plays a major role in innate immunity and inflammatory responses \[[@B8]\] and it is considered the major link between inflammation and tumorigenesis \[[@B1]\]. This factor activates antiapoptotic genes \[[@B9]--[@B11]\] and could promote the transcription of genes associated with growth, invasion, and metastasis, being the key factor that allows precancerous and malignant cells to escape apoptosis \[[@B1]\].

Interleukins (ILs) could stimulate many signaling pathways and thus regulate the transcription of target genes involved in cellular proliferation and survival \[[@B12]\]. Besides that, they act as immune mediators \[[@B13]\] and have been linked to cancer, playing a key role in the recruitment and positioning of leukocytes in carcinogenesis \[[@B14]\]. The recruitment and activation of immune cells and the antitumor effects of IL-4, an anti-inflammatory cytokine, are involved in the inhibition of angiogenesis \[[@B15]\], inflammation, thrombosis, growth, and invasion in some cancers \[[@B16], [@B17]\]. In addition to these effects on stromal cells, some studies have reported that IL-4 has antitumor functions by inducing apoptosis in several types of tumor cells including breast cancer, renal cell carcinoma, and hepatocellular carcinoma \[[@B18]\].

IL-10 is a cytokine produced by Th1 and Th2 cells \[[@B19]\] as well as by tumor cells and has potent immunosuppressive properties \[[@B20]\]. Originally known as an inhibitor factor of the synthesis of cytokines \[[@B7]\], IL-10 suppresses the production of IL-1*α*, IL-1*β*, tumor necrosis factor- (TNF-) *α*, IL-6, IL-8, IL-12, IL-18, granulocytes, inflammatory macrophages, and NF-*κ*B \[[@B7], [@B21], [@B22]\]. This cytokine acts concurrently with IL-3 and IL-4 to stimulate the proliferation of mast cells, peripheral blood lymphocytes \[[@B7]\], and macrophages, and their anti-inflammatory action has been suggested in tumor microenvironment \[[@B22]\].

On the other hand, IL-6 has strong procarcinogenic activity due to its role in tumor cell proliferation, survival, angiogenesis, inflammation, and metastasis \[[@B7], [@B23]\]. In addition, IL-6 is one of the activation signals for NF-*κ*B, promoting cell differentiation and subsequent metastasis \[[@B24]\], thus reinforcing the close link between inflammatory mediators and neoplastic progression \[[@B1]\]. Therefore, TNF-*α* induces proinflammatory cytokines such as IL-1 \[[@B25]\] and IL-6 \[[@B26], [@B27]\], during the inflammatory response \[[@B26]--[@B28]\]. The interaction of this cytokine with its receptor (TNFR) induces apoptotic and antiapoptotic effects in different cell systems \[[@B11]\], and it can promote cell proliferation and inhibits apoptosis in the tumor microenvironment \[[@B29]\], at least indirectly, through the induction of NF-*κ*B \[[@B26]\].

A better understanding of the complexity of these biological factors\' network, together with the characterization of new genes, aids in uncovering the molecular mechanisms of inflammatory diseases and cancer \[[@B30]\]. In this way, the objective of this work was to ascertain the role of anti-inflammatory cytokines, IL-4 and IL-10, and proinflammatory cytokines, IL-6 and TNF-*α*, in mammary tumors of female dogs and to correlate these results with the gene and protein expression of NF-*κ*B. In addition, we sought to verify the correlation of these cytokines with clinicopathological parameters, cancer progression, and overall survival, to determine their prognostic value in mammary tumors.

2. Material and Methods {#sec2}
=======================

2.1. Sample Processing {#sec2.1}
----------------------

Peripheral blood and tumor samples were obtained from 30 female dogs with malignant mammary neoplasia (test group) attended to in São José do Rio Preto, SP, Brazil, veterinary clinics in the years 2011 and 2012. Animals with mammary tumors were included regardless of breed, weight, or age. These animals were followed up for 540 days after tumor excision and blood collection. For control group, peripheral blood samples from 30 female dogs and five samples of mammary tissue adjacent to mammary cancer were obtained from animals that underwent elective hysterectomy as a preventive measure, after completion of the consent form by their owners. The criteria for the control group were rigorously followed and included animals outside the estrus period, animals with no tumor history, and animals with no detectable disease/inflammation in the period or surgery in the next study period. In addition, animals that died of causes other than tumor recurrence or metastasis were excluded from the study.

Peripheral blood (3 mL) was collected in a CORVAC serum separator tube (Labor Import, São Paulo, SP), stored at 4°C, processed by centrifugation (1000 ×g, 25 min), and cryopreserved at −80°C for posterior Enzyme Linked Immunosorbent Assay (ELISA) and xMAP protein analysis. Tumor samples were collected and divided into two pieces. The first one was fixed in 10% formaldehyde buffer for 24 hours and paraffin embedded for histopathology classification after hematoxylin-and-eosin (HE) stain. Tumor grading was ascertained according to Misdorp et al. \[[@B31]\] by the Armed Forces Institute of Pathology (AFIP). The second piece was collected in a Falcon tube containing the RNA-stabilizing solution, RNAlater (Life Technologies®), stored at room temperature for 24 hours, and posteriorly used for RNA extraction and qPCR analysis.

2.2. Clinicopathological Characteristics {#sec2.2}
----------------------------------------

Female dogs from the test group were evaluated with respect to physical (age), pathological (time course (interval between tumor diagnosis and surgical removal), tumor nodules location, lymph node involvement, tumor mass size, clinical staging, ulceration, and vascularization), and clinical (metastasis, local recurrence, and death) characteristics ([Table 1](#tab1){ref-type="table"}). The parameters employed for the classification of clinical tumor grading were in accordance with the TNM (size, lymph node involvement, and metastasis) system established by the World Health Organization (WHO) for canine mammary gland tumors \[[@B32]\]. The clinical grade was assigned as I, II, III, or IV according to the extent of the tumor and the prognosis.

The age of the animals varied from 7 to 14 years (mean = 10 years) and there was predominance of Poodle (19%) and Dachshund (24%) races. In terms of the clinicopathological characteristics, most animals had a tumor for more than six months (54%) and were of clinical stage III or IV (54%). The proportions of animals with lymph node involvement, animals with metastasis/local recurrence, or animals that died during the study were 16%, 27%, and 27%, respectively ([Table 1](#tab1){ref-type="table"}).

2.3. Gene Expression by Quantitative RT-PCR (qPCR) {#sec2.3}
--------------------------------------------------

For total RNA extraction, the tumor samples were manually processed into smaller pieces (100 mg/piece), and the pieces were then immersed in TRIzol reagent (Invitrogen Life Technologies®) and macerated with a Politron (Dremel, Mexico). Previously, tumor samples were treated with DNase and 10x buffer (10 mM Tris-HCl, pH 7.5; 50 mM CaCl~2~; and 10 mM MgCl~2~) (RNeasy Mini Kit, Qiagen) followed by the addition of ethylenediaminetetraacetic acid (EDTA) to deactivate or eliminate proteins binding to template DNA.

The cDNA was synthesized using a High Capacity cDNA kit (Applied Biosystems®). The qPCR was performed in triplicate using the StepOne Plus Real Time PCR system (Applied Biosystems) and TaqMan Universal Master Mix (Applied Biosystems). The following specific primers were used:*NF-κB*, Cf02622551_m1 (Applied Biosystems);*IL-4*, Cf02623112_m1 (Applied Biosystems);*IL-6*, Cf02624153_m1 (Applied Biosystems);*IL-10*, Cf02624265_m1 (Applied Biosystems); and*TNF-α*, Cf02628236_m1 (Applied Biosystems).

The following qPCR conditions were used: an initial step of 2 minutes at 50°C; denaturation for 10 minutes at 95°C; 40 cycles at 95°C for 15 seconds and 60°C for one minute to anneal primers and extend the chains, respectively; and 35 seconds at 65°C to collect the signal. The dissociation curve was generated after amplification and included a step of 15 seconds at 95°C followed by 1 min at 60°C. Each transcript level was normalized to the expression of*RPS19* (sense (5′-GCC TTC CTC AAA AAG TCT GGG-3′), antisense (5′-GCT TGC TCC CTA CGA TGA GAA C-3′), and probe (5′-CCC TGA ATG GGT GGA C-3′) (Applied Biosystems)) and*RPL8,* Cf02663820_m1 (Applied Biosystems), which were used as endogenous control genes.

The relative quantification (RQ) value of the expression of interest genes was determined with DataAssist v3.0, by the quantification method related to the average of the normalizing genes used as endogenous controls (ΔΔCt) \[[@B33]\] and showed by Log~10~. The gene expression of each sample was separately analyzed and classified as underexpressed (samples giving \<0 Log~10~ measurement) and overexpressed (samples with quantification \>0 Log~10~). The samples were tested in triplicate and all experiments included negative controls.

2.4. Protein Expression by ELISA and xMAP Protein Assays {#sec2.4}
--------------------------------------------------------

NF-*κ*B (dog nuclear factor (NF) kappa B p105 subunit (NF-*κ*B1), CUSABIO Biotech Co., Hubei, China) and IL-4 (USCN Life Science Inc., Houston, TX, USA) protein expression analysis was performed according to the manufacturers recommendations. First of all, the plate was precoated with a specific antibody for NF-*κ*B and IL-4. Then, the standards and samples were added in each well and incubated for 2 hours at 37°C. A biotin-conjugated antibody and a horseradish peroxidase- (HRP-) avidin conjugate were added to the plate to amplify the signal and to increase the detectability of the target molecule. A chromogenic substrate (3-3-5-5-tetramethylbenzidine, TMB) was then added to detect the antibody/analyte binding in the reaction. Finally, sulfuric acid (stop solution) was added to stabilize the color development to enable accurate measurement of the intensity at 450 nm.

The analysis of IL-6, IL-10, and TNF-*α* proteins was performed using the MILLIPLEX MAP Kit (CCYTOMAG-90K; Millipore Corporation, USA), and the protein levels were analyzed using the Luminex xMAP MAGPIX (Millipore Corporation, USA). The standard, control, and samples were added to the appropriate wells as were magnetic beads coated with specific antibodies for IL-6, IL-10, and TNF-*α*. The plate was sealed and incubated overnight at 4°C with agitation on a plate shaker. The detecting antibody was added, and the plate was incubated. Streptavidin-phycoerythrin was added to each well to detect antibody/analyte binding. Measurements were performed at 635 nm to excite the magnetic beads and 525 nm to detect phycoerythrin.

The reaction intensity was proportional to the concentration of the cytokines and NF-*κ*B. The calculation of OD was determined through the adjustment curve four-parameter logistic (4-PL) using the SkanIt software for the Multiskan FC 2.5.1.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The results were previously subjected to descriptive analyses for the determination of normality. Clinicopathological characteristics, gene expression, and protein quantification were analyzed in the test and control groups, and the differences between these groups were determined by Student\'s *t*-test or ANOVA followed by the Bonferroni test. All values are expressed as the mean ± standard deviation (SD).

The cutoff points for the protein analyses were established by the receiver operating characteristic (ROC) curve. For the ROC curve, the protein expression levels from female dogs that died were compared with those that survived until the end of the followup period. Survival curves were plotted by the Kaplan-Meier method and the differences between the curves were evaluated by a log-rank test and hazard function.

Spearman\'s rank correlation analysis was performed to describe the correlation between proinflammatory and anti-inflammatory cytokines protein and gene expression with NF-*κ*B. In addition, the mutual relationship between proinflammatory and anti-inflammatory cytokines was analyzed. A multivariate logistic regression analysis was employed to evaluate the simultaneous influence of the prognostic factors on animal death. A *p* value \<0.05 was considered statistically significant. All analyses were performed using GraphPad Prism 4 and StatsDirect software.

3. Results {#sec3}
==========

3.1. Differential Gene and Protein Expression of*NF-κB*,*IL-4*,*IL-10*,*IL-6*, and*TNF-α* Associated with Clinicopathological Features and Survival {#sec3.1}
---------------------------------------------------------------------------------------------------------------------------------------------------

The*NF-κB* gene was significantly overexpressed in animals with tumor time course greater than six months (*p* \< 0.0001); multiple tumor locations (*p* = 0.005); abundant tumor vascularization (*p* = 0.009); tumor mass size greater than three centimeters (cm) (*p* = 0.005); lymph node involvement (*p* = 0.008); metastasis (*p* = 0.02); recurrence (*p* = 0.01); and clinical stage III or IV (*p* \< 0.0001) ([Figure 1(a)](#fig1){ref-type="fig"}).

In the same way, the NF-*κ*B protein expression was significantly higher in animals older than 10 years (*p* = 0.0001), as well as in animals with a tumor time course of less than six months (*p* = 0.001), multiple tumor locations (*p* = 0.01), abundant tumor vascularization (*p* = 0.03), and metastasis (*p* = 0.0005) ([Figure 1(b)](#fig1){ref-type="fig"}). The best cutoff point for NF-*κ*B established by the ROC curve to discriminate the high risk of death was 219.5 pg/mL (sensitivity (95% CI) = 71%, specificity (95% CI) = 41%). No correlation was observed between NF-*κ*B serum levels and survival time (OR 2.003; 95% CI = 0.5553 to 8.983; *p* = 0.29) (data not shown).

*IL-4* was significantly overexpressed in animals aged ≤ 10 years (*p* = 0.02) and animals with tumor time course of less than six months (*p* = 0.01); single tumor location (*p* = 0.0001); moderate tumor vascularization (*p* = 0.0002); tumor mass size less than three centimeters (*p* = 0.0006); no lymph node involvement (*p* = 0.001); metastasis (*p* \< 0.0001); recurrence (*p* = 0.0003); and clinical stage I or II (*p* \< 0.0001) and animals that were still alive at the end of the followup period (*p* \< 0.0001) ([Figure 2(a)](#fig2){ref-type="fig"}).

Therefore, IL-4 protein expression was significantly higher in animals aged ≤ 10 years (*p* \< 0.0001) and animals with tumor time course of less than six months (*p* = 0.04); moderate tumor vascularization (*p* = 0.03); tumor mass size of less than three centimeters (*p* = 0.001); no metastasis (*p* = 0.01); no recurrence (*p* = 0.02); and clinical stage I or II (*p* = 0.008) and animals that were still alive at the end of the followup period (*p* = 0.005) ([Figure 2(b)](#fig2){ref-type="fig"}). Using the ROC curve, the best cutoff point for IL-4 to discriminate the high risk of death was 368.4 pg/mL (sensitivity (95% CI) = 88%, specificity (95% CI) = 95%). The Kaplan-Meier test demonstrated a positive correlation between IL-4 level and survival time (OR 0.068184; 95% CI = 0.783029 to 1; *p* = 0.007) ([Figure 3](#fig3){ref-type="fig"}).

For*IL-10*, significant gene overexpression was also correlated with tumor time course of less than six months (*p* = 0.003); moderate tumor vascularization (*p* = 0.02); no lymph node involvement (*p* = 0.0005); no metastasis (*p* = 0.01); no recurrence (*p* = 0.01); clinical stage I or II (*p* = 0.02); and animals that were still alive at the end of the followup period (*p* = 0.009) ([Figure 4(a)](#fig4){ref-type="fig"}).

Likewise, IL-10 protein expression was significantly higher in animals with tumor time course of less than six months (*p* = 0.003); single tumor location (*p* = 0.0009); moderate vascularization (*p* = 0.04); no recurrence (*p* = 0.04), and clinical stage I or II (*p* = 0.03) and animals that were still alive during the followup (*p* = 0.04) ([Figure 4(b)](#fig4){ref-type="fig"}). For the ROC curve for IL-10, the best cutoff point to discriminate the high risk of death was 243 pg/mL (sensitivity (95% CI) = 100%, specificity (95% CI) = 53%). No correlation was observed between IL-10 protein expression and survival time (OR 0.3267; 95% CI = 0.06811 to 1.564; *p* = 0.16) (data not shown).

In contrast,*IL-6* was significantly overexpressed in animals aged \> 10 years (*p* = 0.03) and animals with multiple tumor locations (*p* = 0.0005); abundant tumor vascularization (*p* = 0.003); tumor mass size greater than three centimeters (*p* = 0.01); lymph node involvement (*p* = 0.04); metastasis (*p* = 0.003); recurrence (*p* = 0.03); and clinical stage III or IV (*p* = 0.02) and animals that died during followup (*p* = 0.008) ([Figure 5(a)](#fig5){ref-type="fig"}).

Similarly, IL-6 protein expression was significantly higher in animals with tumor time course greater than six months (*p* = 0.001); multiple tumor locations (*p* = 0.01); abundant vascularization (*p* = 0.02); tumor mass size greater than three centimeters (*p* = 0.001); lymph node involvement (*p* \< 0.0001); metastasis (*p* \< 0.0001); recurrence (*p* = 0.007); and clinical stage III or IV (*p* = 0.001) and animals that died during followup (*p* = 0.04) ([Figure 5(b)](#fig5){ref-type="fig"}). The best cutoff point for IL-6 established by the ROC curve to discriminate the high risk of death was 76.95 pg/mL (sensitivity (95% CI) = 75%, specificity (95% CI) = 86%). No correlation was observed between IL-6 protein expression and survival time (OR 1.719; 95% CI = 0.4045 to 9.580; *p* = 0.43) (data not shown).

*TNF-α* was also overexpressed in animals with tumor time course greater than six months (*p* = 0.01); multiple tumor locations (*p* = 0.005); abundant tumor vascularization (*p* = 0.007); tumor mass size greater than three centimeters (*p* = 0.02); metastasis (*p* = 0.001); recurrence (*p* = 0.003); and clinical stage III or IV (*p* = 0.0002) and animals that died during followup (*p* = 0.005) ([Figure 6(a)](#fig6){ref-type="fig"}).

The protein expression of TNF-*α* was significantly higher in animals aged \> 10 years (*p* = 0.04) and animals with tumor time course greater than six months (*p* = 0.004); abundant vascularization (*p* = 0.01); lymph node involvement (*p* = 0.0007); metastasis (*p* = 0.02); and recurrence (*p* = 0.01) and animals that died during followup (*p* = 0.04) ([Figure 6(b)](#fig6){ref-type="fig"}). The best cutoff point to discriminate the high risk of death established by the ROC curve was 16.3 pg/mL (sensitivity (95% CI) = 87%, specificity (95% CI) = 62%). This analysis demonstrated a negative correlation between TNF-*α* protein expression and survival time (OR 5.906; 95% CI = 1.387 to 25.6; *p* = 0.01) ([Figure 7](#fig7){ref-type="fig"}).

3.2. Spearman\'s Rank Correlation Analysis between Proinflammatory and Anti-Inflammatory Cytokines with*NF-κB* {#sec3.2}
--------------------------------------------------------------------------------------------------------------

Spearman\'s rank correlation demonstrated that proinflammatory cytokines IL-6 and TNF-*α* are mediated by NF-*κ*B. There was a positive correlation between the proinflammatory TNF-*α* protein and gene expression when compared to NF-*κ*B protein and gene expression (*r* = 0.5233, *p* = 0.003; *r* = 0.6645, *p* \< 0.0001; Figures [8(a)](#fig8){ref-type="fig"} and [8(b)](#fig8){ref-type="fig"}, resp.). In the same way, there was a positive correlation between IL-6 and NF-*κ*B gene expression (*r* = 0.4012; *p* = 0.02) ([Figure 8(b)](#fig8){ref-type="fig"}). Furthermore, the mutual balance between proinflammatory cytokines and anti-inflammatory ones was analyzed by Spearman\'s rank correlation and showed no correlation (*p* \> 0.05; data not shown).

3.3. Multivariate Analysis {#sec3.3}
--------------------------

The multivariate analysis of high levels of the proinflammatory cytokines, low levels of the anti-inflammatory cytokines, and clinicopathological features of poor prognosis with regard to an increased risk of death showed no correlation (*p* \> 0.05) ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

NF-*κ*B is a crucial factor between chronic inflammation and cancer development \[[@B34]\] and it regulates both anti- and proinflammatory cytokines at various stages of tumorigenesis and inflammation \[[@B35], [@B36]\]. We observed high gene and protein expression levels of NF-*κ*B in animals with tumor progression for greater than six months, multiple tumor locations, abundant vascularization, and metastasis, indicating a role of this factor in angiogenesis support and inhibition of apoptosis in tumor cells. In accordance with our prediction, Kiliccioglu et al. \[[@B37]\] observed that NF-*κ*B inhibition, through proteasome inhibition, induces apoptosis in human prostate cancer cell line (PC3), resulting in significantly increased protein levels of caspase-3, which plays a central role in the execution phase of cell apoptosis. Similarly, Chien et al. \[[@B38]\] reported that pancreatic cancer cell growth is suppressed by inhibiting the NF-*κ*B pathway.

In the same way, high protein levels of NF-*κ*B were observed in female dogs above 10 years old which could indicate the correlation between this nuclear factor and cell oxidative stress, leading to tissue damage and chronic inflammation. Corroborating with this, a review of oxidative stress and breast cancer, recently published by Nourazarian et al. \[[@B39]\], suggests that the increase of free radical levels in tumor cells occurs under the influence of the increased expression of cellular enzymes and enhanced activity of some dependent tumor cells, such as cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) \[[@B39], [@B40]\].

Once NF-*κ*B has been activated through one of many pathways, crucial properties of the malignant phenotype are activated, promoting tumor cell adaptation to the tumor environment \[[@B41]\]; then, we also reported*NF-κB* overexpressed in female dogs with tumor masses greater than three centimeters, lymph node involvement, recurrence, and clinical stage III or IV, leading to a poor survival rate of the animals.

It is known that NF-*κ*B is required for the expression of many cytokine genes that encode proteins associated with inflammatory mediators \[[@B42]\]. Then, through Spearman\'s rank correlation, we showed that high expression of NF-*κ*B modulates positively the IL-6 and TNF-*α* expression levels in mammary tumors. The proinflammatory cytokines IL-1*β*, IL-6, and TNF-*α* could be modulated by lipopolysaccharides (LPS) administration as it occurs in inflammatory diseases. According to Cheon et al. \[[@B43]\], some drugs, as saxifragin, inhibited the LPS-induced nuclear translocation of p65 and the activation of caspase-1 in RAW 264 cells, suggesting that the NF-*κ*B-regulated gene transcription is responsible for anti-inflammatory response of macrophages. In addition, Osnes et al. \[[@B44]\] affirmed that the inhibitory synthesis of TNF-*α* by drugs as acetylsalicylic acid and sodium salicylate in human monocytes is due to interfering of nuclear translocation of NF-*κ*B/c-Rel proteins.

Besides that, corroborating with our study, Al-Halabi et al. \[[@B34]\] showed that the inhibition of NF-*κ*B significantly lowers microvessel density (CD31) and mRNA expression levels of IL-6, TNF-*α*, and IL-1*α*, as well as protein levels of proliferation marker (Ki-67) and vascular endothelial growth factor- (VEGF-) A in human colon cancer, confirming the primordial role of NF-*κ*B in angiogenesis and, therefore, tumor progression.

Regarding anti-inflammatory interleukins, our study sustains a protector action of the anti-inflammatory cytokines IL-4 and IL-10 in female dogs\' mammary tumors. IL-4 was highly expressed in gene and protein levels in female dogs with a better prognostic. This cytokine acts on endothelial cells, inhibiting tumor-induced vascularization and starving tumor cells \[[@B45]\], and also induces secretion of IL-10, the Th2 cytokine with a strong suppressive effect on tumors \[[@B46], [@B47]\], which could explain high levels of this cytokine in animals that are still alive after the followup period and in overall survival. Furthermore, according to Okada and Kuwashima \[[@B45]\], the sustained expression of IL-4 may provide effective means for therapy of a variety of diseases, including cancer.

In addition, high gene and protein expression of IL-10 were correlated with characteristics of better prognosis. IL-10 downregulates proinflammatory cytokine expression \[[@B48], [@B49]\] and inhibits the expression of CD31 \[[@B50]\]. Lin and Karin \[[@B48]\] reported that IL-10 could modulate apoptosis and suppress angiogenesis during tumor regression, downregulating VEGF, TNF-*α*, and IL-6 production by TAMs. Jindal and Borges \[[@B51]\] showed that IL-10 inhibits tumor growth by preventing chemokine expression and angiogenesis when administered at higher doses in cancer animal models. Li et al. \[[@B52]\] correlated high IL-10 expression in female dogs with no metastasis or recurrence and high overall survival. Contrarily, gene overexpression of*IL-10* in animals that had metastasis could suggest posttranscriptional regulation of this cytokine, once the protein levels do not show this correlation.

IL-6 mediates a plethora of physiological functions, including the developmental differentiation of lymphocytes, cell proliferation, and cell survival during tumorigenesis \[[@B48], [@B53]\]. This cytokine had high gene and protein expression correlated with poor prognosis and a negative correlation was found in animals that died during the followup. In the same way, a study by Madeddu et al. \[[@B54]\] demonstrated high expression of IL-6 through activation of Akt/PI3K/mTOR cascade due to elevated oxidative stress, promoting oncogenesis and tumor progression. Owing to its association with poor prognosis, researchers have proposed IL-6 as a therapeutic target in cancer \[[@B49]\]. Several phase I/II clinical trials are currently evaluating antibodies against IL-6 or IL-6R as therapeutic alternatives for prostate cancer \[[@B53], [@B55]\] and renal cancer \[[@B56], [@B57]\]. These results suggest that further studies are needed to determine the appropriate use of anti-interleukin monoclonal antibodies as a therapeutic treatment, and studies similar to ours, evaluating interleukin expression, may be useful as a foundation for further clinical trials of therapy using cytokines.

TNF-*α* is a cytokine that promotes tumorigenesis under conditions of unresolved inflammation \[[@B49]\]. Increasing lines of evidence suggest that TNF-*α* regulates many of the critical processes of tumor promotion and progression \[[@B48], [@B58]\]. In our study, high protein levels of TNF-*α* were found in animals that died during the followup and correlated with worse prognostic features. Its cytokine has been implicated yet as a tumor promoter in different tumor types like ovarian cancer \[[@B59]\], gallbladder cancer \[[@B60]\], and oral squamous cell carcinoma \[[@B61]\]. TNF-*α* binds to two receptors, namely, the ubiquitously expressed TNF receptor 1 (TNFR1) and hematopoietically restricted TNFR2, and modulates a signaling cascade that induces mediators of transcriptional regulation that are key to cell survival, invasion, angiogenesis, and impairment of immune surveillance in tumor biology \[[@B49], [@B58], [@B59], [@B62]\].

Altogether, our data showed the effect of cytokines on tumor development and progression, as well as positive modulation of NF-*κ*B and proinflammatory interleukins in mammary tumors. Analysis of the active genes and proteins in cancer can be used to target treatment more specifically, and our results suggest the use of these biological factors as prognostic biomarkers in cancer.

5. Conclusion {#sec5}
=============

Our results are of utmost importance for a better understanding of the dynamic network of cytokines and the influence of NF-*κ*B on tumorigenesis. These cytokines could be employed as noninvasive prognostic markers in female dogs with mammary tumors and could be useful for predicting disease progression and tumor recurrence. There is lack of studies devoted to diagnostic, therapeutic, and prognostic markers in canine mammary tumors; so, this study defines potential prognostic and predictive markers for routine use in the clinic, allowing the detection of recurrence and metastasis, which could allow the early adoption of more precise conduct to improve the overall survival of animals.
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![*NF-κB* gene overexpression correlated with (a) tumor progression greater than 6 months; multiple tumor locations; abundant tumor vascularization; tumor mass size greater than 3 cm; lymph node involvement; presence of metastasis; recurrence and clinical staging III or IV. Higher NF-*κ*B protein levels correlated with (b) with age \> 10 years; tumor progression greater than 6 months; multiple tumor locations; abundant tumor vascularization; and presence of metastasis. Error bars ± standard error; ^*∗*^ *p* \< 0.05; ^*∗∗*^ *p* \< 0.01; ^*∗∗∗*^ *p* \< 0.001 indicate significant differences according to Student\'s *t*-test.](MI2016-9512743.001){#fig1}

![*IL-4* gene overexpression correlated with (a) age ≤ 10 years; tumor progression for less than 6 months; single tumor location; moderate tumor vascularization; tumor mass size less than 3 cm; no lymph node involvement; no metastasis; no recurrence; clinical staging I or II; and animals that were alive at the end of the followup period. Higher IL-4 protein levels correlated with (b) with age ≤ 10 years; tumor progression for less than 6 months; moderate tumor vascularization; tumor mass size less than 3 cm; no metastasis; no recurrence; clinical staging I or II; and animals that were alive at the end of the followup period. Error bars ± standard error; ^*∗*^ *p* \< 0.05; ^*∗∗*^ *p* \< 0.01; ^*∗∗∗*^ *p* \< 0.001 indicate significant differences according to Student\'s *t*-test.](MI2016-9512743.002){#fig2}

![Survival curve of IL-4. Tumors of female dogs with high expression (black line) of IL-4 had lower chance of death compared with animals with low expression (dotted line). *p* = 0.007.](MI2016-9512743.003){#fig3}

![*IL-10* gene overexpression correlated with (a) tumor progression for less than 6 months; moderate tumor vascularization; no lymph node involvement; no metastasis; no recurrence; clinical staging I or II; and animals that were alive at the end of the followup period. Higher IL-10 protein levels correlated with (b) tumor progression for less than 6 months; single tumor location; moderate tumor vascularization; no recurrence; clinical staging I or II; animals that were alive at the end of the followup period. Error bars ± standard error; ^*∗*^ *p* \< 0.05; ^*∗∗*^ *p* \< 0.01; ^*∗∗∗*^ *p* \< 0.001 indicate significant differences according to Student\'s *t*-test.](MI2016-9512743.004){#fig4}

![*IL-6* gene overexpression correlated with (a) age ≤ 10 years; multiple tumor locations; abundant tumor vascularization; tumor mass size greater than 3 cm; lymph node involvement; metastasis; recurrence; clinical staging III or IV; and animals that died. Higher IL-6 protein levels correlated with (b) tumor progression for more than 6 months; multiple tumor locations; abundant tumor vascularization; tumor mass size greater than 3 cm; lymph node involvement; metastasis; recurrence; clinical staging III or IV; and animals that died. Error bars ± standard error; ^*∗*^ *p* \< 0.05; ^*∗∗*^ *p* \< 0.01; ^*∗∗∗*^ *p* \< 0.001 indicate significant differences according to Student\'s *t*-test.](MI2016-9512743.005){#fig5}

![*TNF-α* gene overexpression correlated with (a) tumor progression for more than 6 months; multiple tumor locations; abundant tumor vascularization; tumor mass size greater than 3 cm; metastasis; recurrence; clinical staging III or IV; and animals that died. Higher TNF-*α* protein levels correlated with (b) age \> 10 years; tumor progression for more than 6 months; abundant tumor vascularization; lymph node involvement; metastasis; recurrence; and animals that died (*p* = 0.04). Error bars ± standard error; ^*∗*^ *p* \< 0.05; ^*∗∗*^ *p* \< 0.01; ^*∗∗∗*^ *p* \< 0.001 indicate significant differences according to Student\'s *t*-test.](MI2016-9512743.006){#fig6}

![Survival curve of TNF-*α*. Tumors of female dogs with high expression (dotted line) of TNF-*α* had higher chance of death compared with animals with low expression (black line). *p* = 0.01.](MI2016-9512743.007){#fig7}

![Spearman\'s rank correlation analysis between proinflammatory and anti-inflammatory cytokines with NF-*κ*B protein and gene expression: (a) positive correlation between NF-*κ*B protein expression and the proinflammatory TNF-*α* cytokine protein expression (*r* = 0.5233; *p* = 0.003) and (b) NF-*κ*B gene expression and its correlation between the proinflammatory TNF-*α* cytokine (*r* = 0.6645; *p* \< 0.0001) and IL-6 (*r* = 0.4012; *p* = 0.02) gene expression. ^*∗*^ *p* \< 0.05.](MI2016-9512743.008){#fig8}

###### 

Clinicopathological parameters of female dogs with mammary tumors.

  Clinicopathological parameters   Number of dogs
  -------------------------------- ----------------
  Age of animals                    
   \>10 years                      14 (53%)
   ≤10 years                       16 (47%)
  Tumor time course                 
   \>six months                    16 (54%)
   ≤six months                     14 (44%)
  Tumor location                    
   Multiple                        14 (44%)
   Single                          16 (54%)
  Vascularization                   
   Moderate                        20 (66%)
   Abundant                        10 (34%)
  Tumor mass size                   
   T1                              15 (50%)
   T2/T3                           15 (50%)
  Lymph node involvement            
   N0                              25 (84%)
   N1/N2                           5 (16%)
  Metastasis                        
   Yes                             8 (27%)
   No                              22 (73%)
  Clinical staging                  
   I and II                        14 (44%)
   III and IV                      16 (54%)
  Recurrence                        
   Yes                             8 (27%)
   No                              22 (73%)
  Censorship                        
   Death                           8 (27%)
   Alive                           22 (73%)

###### 

Multivariate analysis of proinflammatory and anti-inflammatory cytokines and clinicopathological features of poor prognosis with regard to an increased risk of death.

  Cytokines   OD         95% CI                  *p* value
  ----------- ---------- ----------------------- -----------
  IL-4        7.819735   0.48417 to 126.294945   0.1
  IL-6        1.3169     0.09401 to 18.447342    0.8
  IL-10       0.199689   0.01511 to 2.639014     0.2
  TNF-*α*     0.259712   0.011486 to 5.872229    0.3
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